Skip to Main Content

Paper Details

Tolerability and toxicity of trastuzumab or trastuzumabâ¿¿+â¿¿lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D).
Breast Cancer Res Treat
3
2021
HER2, HER2-positive BC, Lapatinib, N063D, Trastuzumab, comorbidities, lapatinib, patients, patients65, trastuzumab
Author NameAffiliation
Lissandra Dal LagoInstitut Jules Bordet
Larissa A KordeNational Cancer Institute
Florentine S Hilbers
Christos SotiriouInstitut Jules Bordet
  • 1 - 4

Datasets

Release 1.2